Company addresses problem affecting millions of colonoscopies annually

NORMAN, OK, UNITED STATES, November 14, 2023 /EINPresswire.com/ -- Boyd Street Ventures announced that it has invested in BP Endo, which has developed a breakthrough solution to the air or fluid incontinence that compromises nearly four million colonoscopy procedures annually in the U.S.

A colonoscopy is an important procedure for screening for colon cancer, removing polyps, and controlling lower gastrointestinal bleeding. “If air or fluid incontinence occurs during the procedure, the exam cannot be performed efficiently,” said Dr. Robert Holbrook, a gastroenterologist and Founder and CEO of BP Endo. In a study conducted by Dr. Holbrook’s alma mater, the University of Oklahoma College of Medicine, incontinence occurred in roughly one-quarter of colonoscopies. This problem causes great inconvenience for patients, and BP Endo estimates that it costs the average gastroenterologist approximately $15,000 annually. Said Dr. Holbrook, “We’ve developed an affordable solution that allows endoscopists to complete exams and interventions more efficiently, decreasing the burden and costs on patients, staff, and payors.”

The solution BP Endo has developed is the world’s first Insufflation Retention Device, or IRD, which attaches to an endoscope. After the endoscope is inserted into the rectum, the IRD is inflated with a syringe to seal the colon from any air or fluid incontinence in about 30 seconds. Upon inflation, the colon is sealed and the endoscopist is given full freedom of movement and sight. The IRD is patented, has received FDA 510(k) clearance, and is legally prepared to begin production.

“Over 16 million colonoscopies are conducted in the U.S. every year, and roughly four million of them are compromised by air or fluid incontinence,” said James Spann, Founder and General Partner at Boyd Street Ventures. “We feel that BP Endo has developed a brilliant and unique solution to this problem, and we look forward to supporting their efforts to take this solution to market to the benefit of millions of patients and thousands of gastroenterologists.” Mr. Spann added that BP Endo will participate in the Boyd Street Venture Studio, where it will receive strategic and operational guidance to accelerate its time to market and increase its ability to scale.

About Boyd Street Ventures

Boyd Street Ventures is a groundbreaking, early-stage venture capital firm connecting institutional and other investors to high-growth investment opportunities developed within the ecosystem of University of Oklahoma – recipient of the Carnegie Classification’s highest rating for research activity – and by OU alums and other Oklahoma-affiliated entrepreneurs. BSV places Pre-Seed, Seed, Series A and follow-on investments in the Life Sciences, FinTech, Energy Tech, Aerospace & Defense, and Climate Tech sectors. The firm focuses on under-the-radar startups that are less likely to have their prices overbid and overpriced than startups targeted by larger VC firms on the East and West Coasts. This focus, coupled with its unusually active involvement in providing de-risking strategic and operational counsel to its portfolio companies through its Boyd Street Venture Studio, enables BSV to target above-average returns for its investors. For more information, please visit https://www.boydstreetventures.com/

John Pohl, Venture Partner, Marketing & Investor Relations
Boyd Street Ventures
+1 847-812-2879
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
YouTube

Boyd Street Ventures 3-Minute Video

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.